BACKGROUND: The optimal properties of a comprehensive (level II) neuropsychological battery for determining Parkinson's disease mild cognitive impairment (PD-MCI) by Movement Disorder Society (MDS) Task Force criteria remain unresolved. METHODS: Seventy-six nondemented PD patients underwent PD-MCI classification using a consensus diagnosis and level II criteria. We examined the optimal number of tests in each of the five designated cognitive domains, identified the best tests within each domain, and determined the best overall battery for PD-MCI level II diagnosis. RESULTS: A battery with two tests per domain provided a highly practical, robust diagnostic assessment. Level II testing with the two best tests and impairment defined as 2 standard deviations below norms was highly sensitive and specific for PD-MCI diagnosis. CONCLUSIONS: Our findings strongly support the MDS Task Force Level II testing recommendations, provide a framework for creating an optimal, efficient neuropsychological test battery for PD-MCI diagnosis, and offer specific test recommendations.
BACKGROUND: The optimal properties of a comprehensive (level II) neuropsychological battery for determining Parkinson's disease mild cognitive impairment (PD-MCI) by Movement Disorder Society (MDS) Task Force criteria remain unresolved. METHODS: Seventy-six nondemented PD patients underwent PD-MCI classification using a consensus diagnosis and level II criteria. We examined the optimal number of tests in each of the five designated cognitive domains, identified the best tests within each domain, and determined the best overall battery for PD-MCI level II diagnosis. RESULTS: A battery with two tests per domain provided a highly practical, robust diagnostic assessment. Level II testing with the two best tests and impairment defined as 2 standard deviations below norms was highly sensitive and specific for PD-MCI diagnosis. CONCLUSIONS: Our findings strongly support the MDS Task Force Level II testing recommendations, provide a framework for creating an optimal, efficient neuropsychological test battery for PD-MCI diagnosis, and offer specific test recommendations.
Authors: Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins Journal: Mov Disord Date: 2013-10-09 Impact factor: 10.338
Authors: John A Schinka; David A Loewenstein; Ashok Raj; Mike R Schoenberg; Jessica L Banko; Huntington Potter; Ranjan Duara Journal: Am J Geriatr Psychiatry Date: 2010-08 Impact factor: 4.105
Authors: J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark Journal: Neurology Date: 1989-09 Impact factor: 9.910
Authors: Jennifer G Goldman; Reena A Ghode; Bichun Ouyang; Bryan Bernard; Christopher G Goetz; Glenn T Stebbins Journal: Parkinsonism Relat Disord Date: 2013-06-02 Impact factor: 4.891
Authors: Nicole Licking; Charles Murchison; Brenna Cholerton; Cyrus P Zabetian; Shu-Ching Hu; Thomas J Montine; Amie L Peterson-Hiller; Kathryn A Chung; Karen Edwards; James B Leverenz; Joseph F Quinn Journal: Parkinsonism Relat Disord Date: 2017-08-09 Impact factor: 4.891
Authors: Seok Jong Chung; Han Soo Yoo; Yang Hyun Lee; Hye Sun Lee; Byoung Seok Ye; Young H Sohn; Hunki Kwon; Phil Hyu Lee Journal: Hum Brain Mapp Date: 2019-05-14 Impact factor: 5.038
Authors: Tess E K Cersonsky; Sarah Kellner; Silvia Chapman; Edward D Huey; Elan D Louis; Stephanie Cosentino Journal: J Int Neuropsychol Soc Date: 2019-10-04 Impact factor: 2.892
Authors: Samantha K Holden; Luis D Medina; Brian Hoyt; Stefan H Sillau; Brian D Berman; Jennifer G Goldman; Daniel Weintraub; Benzi M Kluger Journal: Mov Disord Date: 2018-10-10 Impact factor: 10.338